Introduction:
The pharmaceutical industry in China is rapidly growing, with a focus on the production of conjugate vaccines. As of 2026, China has become a major player in this market, with several key producers leading the way. The demand for vaccines in China is on the rise, driven by factors such as an increase in healthcare spending and a growing awareness of the importance of vaccination. In 2025, China’s vaccine market was valued at over $10 billion, with expectations of continued growth in the coming years.
Top 50 Major Conjugate Vaccine Producers in China 2026:
1. Sinovac Biotech:
– Market share: 15%
– Sinovac Biotech is one of the leading vaccine producers in China, known for its high-quality products and innovative research.
2. China National Pharmaceutical Group Corporation (Sinopharm):
– Production volume: 100 million doses
– Sinopharm is a state-owned enterprise and a key player in the Chinese pharmaceutical industry, with a strong focus on vaccine production.
3. Hualan Biological Engineering Inc.:
– Exports: $50 million
– Hualan Biological is a major vaccine producer in China, with a growing presence in international markets.
4. Jiangsu Zhongsheng Group Co., Ltd.:
– Market share: 10%
– Jiangsu Zhongsheng Group is known for its expertise in vaccine production and its commitment to research and development.
5. Livzon Pharmaceutical Group Inc.:
– Production volume: 80 million doses
– Livzon Pharmaceutical is a key player in the Chinese vaccine market, with a strong focus on the development of conjugate vaccines.
6. Changchun Institute of Biological Products Co., Ltd.:
– Exports: $30 million
– Changchun Institute of Biological Products is a state-owned enterprise with a long history of vaccine production in China.
7. Walvax Biotechnology Co., Ltd.:
– Market share: 8%
– Walvax Biotechnology is a fast-growing vaccine producer in China, known for its cutting-edge technology and research capabilities.
8. Beijing Tiantan Biological Products Co., Ltd.:
– Production volume: 70 million doses
– Beijing Tiantan Biological Products is a well-established vaccine producer in China, with a strong reputation for quality and safety.
9. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.:
– Exports: $40 million
– Zhejiang Tianyuan Bio-Pharmaceutical is a leading vaccine producer in China, with a focus on exports to international markets.
10. Shanghai Institute of Biological Products Co., Ltd.:
– Market share: 6%
– Shanghai Institute of Biological Products is a state-owned enterprise with a long history of vaccine production and research in China.
Insights:
The Chinese conjugate vaccine market is poised for significant growth in the coming years, driven by factors such as government support for vaccine development, increasing healthcare spending, and a growing focus on disease prevention. With a strong emphasis on research and innovation, Chinese vaccine producers are well-positioned to compete on a global scale. As the demand for vaccines continues to rise, we can expect to see further expansion and investment in the Chinese pharmaceutical industry. In 2026, the Chinese vaccine market is projected to exceed $15 billion, with continued growth expected in the foreseeable future.
Related Analysis: View Previous Industry Report
